



IN THIS ISSUE

- Welcome
- New Publications
- Regulatory Update
- Core Protocol V4.0
- Recruitment

Dear friends,

As we are enjoying the summer weather, we are already anticipating winter time. The Ecraid team has worked hard to submit our next SM to CTIS, and are planning training sessions on Core v4.0 and the new (reduced) version of the CRF. We are planning several activities to further strengthen our network, and continue to provide (online) education through Ecraid and it's collaboration with ESCMID and ERS. The first non-COVID primary result of REMAP-CAP was recently published, bringing us a step further in understanding which patients with CAP could benefit from corticosteroids. I am also very happy to see our analysis of EARL hurdles published - it gives great insight into how challenging the delivery of multinational adaptive platform trials can be, even in a pandemic, and underlines we should be proud of what we have done together to date. For now, I wish you all a good summer, hopefully with some time off!

Lennie

Top 3 recruiting sites from April 1st

1. Meander Medisch Centrum (NL)
2. Poole Hospital NHS Foundation Trust (UK)
3. Ramon y Cajal University Hospital (ES)

Postgraduate Course Ecraid x ESCMID

Are you an early-career researcher in clinical microbiology and infectious diseases using epidemiological and statistical methods? Join the 'Better Methods for Clinical Studies in Infectious Diseases and Clinical Microbiology' organised by Ecraid and ESCMID! Attendance grants available. More info

Postgraduate course

Better methods for clinical studies in infectious diseases and clinical microbiology

28-30 October 2025
Athens, Greece

REGISTER TODAY



Core Protocol V4.0

Currently, the operational team is finalizing all necessary educational materials to train and activate participating sites on Core Protocol V4.0 and other updated protocol documents.

Active sites will be invited to participate in a general training that will take place after the eCRF update for Core Protocol Version 4 is released. This is expected in Q3 2025.

New Publications

Corticosteroid Domain

We are pleased to share with you a new REMAP-CAP publication titled "[Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia](#)" published in Intensive Care Medicine.

In the REMAP-CAP trial, critically ill adults with severe CAP were randomized to receive either a 7-day course of intravenous hydrocortisone or no corticosteroid. The primary outcome was 90-day all-cause mortality, analyzed using a Bayesian model. Results suggest that hydrocortisone is unlikely to significantly reduce mortality, though smaller benefits or potential harm cannot be ruled out. You can access the article [here](#).

This work reflects the continued efforts and collaboration within our research community.

Learning from REMAP-CAP

We are proud to share that REMAP-CAP contributed to important work on improving how clinical trials are conducted across borders. As many of you know firsthand, conducting clinical research, especially during a public health emergency such as a pandemic, requires navigating a complex web of ethical, administrative, regulatory, and logistical (EARL) requirements. In a recent [publication](#), we aimed to provide insights into where improvements could be made and analyzed EARL timelines in different countries, such as time to first patient enrollment. The results show the extraordinary amount of work of all teams across Europe. It was found that some countries, such as the UK and also France, were able to accelerate timelines substantially during the COVID-19 pandemic. In other settings, there were still challenges, particularly in long contracting timelines. We hope that these findings spark further conversation about how we can collectively streamline EARL processes to ensure that patients across Europe can keep benefitting from innovative research. Article can be found [here](#). Invited commentary can be found [here](#).

White Paper - Ecraid

This whitepaper offers a comprehensive overview of the APT landscape. APTs have demonstrated success in the rapid evaluation of multiple therapies. A case study on REMAP-CAP describes the impact of our trial and it's design. You can download the white paper [here](#).

Regulatory Update

The DSUR has been submitted within CTIS on the 5th of June, as have for the UK and Serbia on the 9th of June. All sites will receive a copy upon approval.

We'd like to inform you that have submitted a Substantial Modification for REMAP-CAP on June 20. This update included several changes to the study documentation, such as updates to the SmPCs and Immune Modulation protocol (additional exclusion criteria). It will also involve the rollout of biosampling for the Immune Modulation domain (IMPRINT) in the Netherlands.

If any of these changes are applicable to your country or site, we will keep you informed with further details.

For live EU region enrolment data click [here](#)

World

- [298 sites](#)
- [15,103 unique patients](#)
- [10,450 COVID-19 patients](#)
- [25,877 randomisations](#)

European region

- [97 sites](#)
- [8,496 unique patients](#)
- [6,863 COVID-19 patients](#)
- [15,614 randomisations](#)

Let's connect



The ECRAID-Base project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 965313

